Trial · NCT04331899

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

NCT04331899, Phase 2, Completed, Stanford University; results first posted 2021-04-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19. Trials, record NCT04331899. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04331899

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
NCT number: NCT04331899
Status: Completed
Phases: Phase 2
Enrollment: 120 participants, actual
Lead sponsor: Stanford University
Conditions: COVID-19
Interventions: Peginterferon Lambda-1a, Placebo
First posted: 2020-04-02
Last updated: 2021-11-30
Results first posted: 2021-04-22

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Duration Until Viral Shedding Cessation	Assessed for up to 28 days	Time to first of two consecutive negative respiratory secretions obtained by oropharyngeal and/or anterior nare swabs for SARS-CoV-2 by qRT-PCR.
Secondary	Change in Sars-CoV-2 Viral Load	baseline, day 14	Log10 Oropharyngeal viral load over time, mean change at day 14 (SD). Sars-CoV-2 RNA level in oropharyngeal and/or anterior nare swabs collected daily.
Secondary	Area Under the Curve of SARS-COV-2 Viral Load	baseline through day 14	Log10 viral load area under the curve through day 14, median (IQR). Area under the curve of SARS-CoV-2 viral load in oropharyngeal and/or anterior nare swabs collected daily.
Secondary	Duration Until Resolution of Symptoms	Up to 28 days	Duration until resolution of symptoms in days, median (95% CI). Time to alleviation of all symptoms (fever, chills, cough, nasal congestion, muscle pains), defined as the time from initiation of treatment until all symptoms are rated as absent or mild in symptomatic patients.
Secondary	Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment	28 days

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Duration Until Viral Shedding Cessation	Assessed for up to 28 days	days	MEDIAN
SECONDARY	Change in Sars-CoV-2 Viral Load	baseline, day 14	Log10 copies per mL	MEAN
SECONDARY	Area Under the Curve of SARS-COV-2 Viral Load	baseline through day 14	Log10 copies*days/ml	MEDIAN
SECONDARY	Duration Until Resolution of Symptoms	Up to 28 days	days	MEDIAN
SECONDARY	Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment	28 days	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Duration Until Viral Shedding Cessation	Lambda		7	95% Confidence Interval 5 to 13	days
Duration Until Viral Shedding Cessation	Placebo		7	95% Confidence Interval 5 to 10	days
Change in Sars-CoV-2 Viral Load	Lambda		-4.3	Standard Deviation 1.3	Log10 copies per mL
Change in Sars-CoV-2 Viral Load	Placebo		-4.9	Standard Deviation 4.7	Log10 copies per mL
Area Under the Curve of SARS-COV-2 Viral Load	Lambda		28.5	Inter-Quartile Range 18.6 to 39.1	Log10 copies*days/ml
Area Under the Curve of SARS-COV-2 Viral Load	Placebo		29.6	Inter-Quartile Range 19.6 to 38.7	Log10 copies*days/ml
Duration Until Resolution of Symptoms	Lambda		8	95% Confidence Interval 6 to 11	days
Duration Until Resolution of Symptoms	Placebo		9	95% Confidence Interval 5 to 11	days
Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment	Lambda	Hospitalizations	2		Participants
Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment	Placebo	Hospitalizations	2		Participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Trial Period (28 Days)	STARTED	Lambda	60
Trial Period (28 Days)	STARTED	Placebo	60
Trial Period (28 Days)	COMPLETED	Lambda	58
Trial Period (28 Days)	COMPLETED	Placebo	58
Trial Period (28 Days)	NOT COMPLETED	Lambda	2
Trial Period (28 Days)	NOT COMPLETED	Placebo	2
Follow-up Period (10 Months)	STARTED	Lambda	42
Follow-up Period (10 Months)	STARTED	Placebo	43
Follow-up Period (10 Months)	COMPLETED	Lambda	42
Follow-up Period (10 Months)	COMPLETED	Placebo	43

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Elevated liver function test	Hepatobiliary disorders	Lambda	15	60
other	Elevated liver function test	Hepatobiliary disorders	Placebo	5	60
serious	Hypoxia (hospital admission)	Respiratory, thoracic and mediastinal disorders	Lambda	2	60
serious	Hypoxia (hospital admission)	Respiratory, thoracic and mediastinal disorders	Placebo	2	60

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Lambda	0	60
Total, all-cause mortality	Placebo	0	60
Total, other adverse events	Lambda	15	60
Total, other adverse events	Placebo	5	60
Total, serious adverse events	Lambda	2	60
Total, serious adverse events	Placebo	2	60

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
33624010	DERIVED	PubMed
33785743	RESULT	PubMed
35588734	DERIVED	PubMed
37147857	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Lambda vs Placebo: deaths from any cause	Trial comparisons
Lambda vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04331899

GET https://conductscience.org/api/trials/v1/NCT04331899/registered

API reference For AI assistants